Goldline Pharmaceutical IPO was subscribed 840.74 times on the last day. A retail quota was subscribed to over 881.15 times, and NII was subscribed to over 1,662.04 times, respectively. The QIB was 180.22 times subscribed on the last day.
Goldline Pharmaceutical IPO Listing Details
| Listing Date | May 19, 2026 |
| BSE Code | 544759 |
| ISIN Code | INE1CLW01015 |
| Offer Price | ā¹41 to ā¹43 |
| Face Value | ā¹10 |
| Listing Price | 59.75 |
Details About the Goldline Pharmaceutical IPO
Goldline Pharmaceutical IPO received SEBI approval for an IPO worth ā¹11.61 crores via fresh issue with the face value of ā¹10 each.
Further, the Goldline Pharmaceutical IPO had a set price band of ā¹41 to ā¹43 per share.
Goldline Pharmaceutical IPO consists of 6000 shares in 2 lot sizes for retail minimum and maximum categories.
S-HNI Minimum has a share of 9000 in a 3-lot size. S-HNI Maximum has 21,000 shares in 7 lot sizes. While 24,000 shares were in 8 lot sizes for the B-HNI category.
To invest in the Goldline Pharmaceutical IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum and maximum investment of ā¹2,58,000.
- SHNI (S-HNI): Minimum investment of ā¹3,87,000.
- S-HNI Maximum investment of ā¹9,03,000.
- B-HNI Minimum investment of ā¹10,32,000.
Goldline Pharmaceutical IPO Subscription Duration
Goldline Pharmaceutical IPO opened on May 12, 2026, and closed on May 14, 2026. The Goldline Pharmaceutical IPO allotment date was scheduled on May 15, 2026. The Goldline Pharmaceutical IPO listing date is on May 19, 2026.
Goldline Pharmaceutical IPO funds deployment
The proceeds of the fresh issue will be used towards the repayment/prepayment of existing borrowings taken by the company.
Lastly, the remaining funds will be used for general corporate purposes.
About the Goldline Pharmaceutical IPO Company
Goldline Pharmaceutical, on February 28, 2005, is a fast-growing, diversified pharmaceutical company operating across 5 segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. Goldline Pharmaceutical is the company that offers a diverse range of tablets and capsules under various specialties.
The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline. The firm is backed by experienced promoters and a management team with over 50 years of experience in the pharma industry.
Goldline Pharmaceutical IPO Company Financial Report
The company reported revenue of ā¹28.06 crores in 2025 against ā¹23.57 crores in 2024. The company reported a profit of ā¹2.83 crores in 2025 against a profit of ā¹1.81 crores in 2024.
